【港股通】上海医药(02607)子公司研发的甲钴胺片通过国家药监局仿制药一致性评价

金吾财讯08-05

金吾财讯 | 上海医药(02607)公布，控股子公司上海新亚药业闵行有限公司，收到国家药品监督管理局颁发的关于甲钴胺片的《药品补充申请批准通知书》(通知书编号：2024B03245)，该药品通过仿制药一致性评价。据悉甲钴胺片主要用于周围神经病，由日本卫材研发，最早于1981年在日本上市。2022年11月，新亚闵行就该药品仿制药一致性评价向国家药监局提出申请并获受理。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2457749367?lang=zh_CN&edition=full","thumbnail":"https://static.szfiu.com/news/20210810/OWQwNTk1YTkxMThhNDViMzhlZTk4MmY1MjNjNTJjMTgxNDI5NTA5OTg3NA==.jpg","is_english":false,"pubTime":"2024-08-05 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2457749367","market":"sg","top_or_hot":-1,"title":"【港股通】上海医药(02607)子公司研发的甲钴胺片通过国家药监局仿制药一致性评价","media":"金吾财讯","content":"<html><body><p>金吾财讯 | <a href=\"https://laohu8.com/S/601607\">上海医药</a>(02607)公布，控股子公司上海新亚药业闵行有限公司，收到国家药品监督管理局颁发的关于甲钴胺片的《药品补充申请批准通知书》(通知书编号：2024B03245)，该药品通过仿制药一致性评价。据悉甲钴胺片主要用于周围神经病，由日本卫材研发，最早于1981年在日本上市。2022年11月，新亚闵行就该药品仿制药一致性评价向国家药监局提出申请并获受理。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【港股通】上海医药(02607)子公司研发的甲钴胺片通过国家药监局仿制药一致性评价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【港股通】上海医药(02607)子公司研发的甲钴胺片通过国家药监局仿制药一致性评价\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-05 17:06 北京时间&nbsp;&nbsp;&nbsp;<a href=1941688><strong>金吾财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 上海医药(02607)公布，控股子公司上海新亚药业闵行有限公司，收到国家药品监督管理局颁发的关于甲钴胺片的《药品补充申请批准通知书》(通知书编号：2024B03245)，该药品通过仿制药一致性评价。据悉甲钴胺片主要用于周围神经病，由日本卫材研发，最早于1981年在日本上市。2022年11月，新亚闵行就该药品仿制药一致性评价向国家药监局提出申请并获受理。</p>\n\n<a href=\"1941688\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1197","symbol_name":"保健护理产品经销商","start_time":0,"source_url":"1941688","article_id":"2457749367","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20210810/OWQwNTk1YTkxMThhNDViMzhlZTk4MmY1MjNjNTJjMTgxNDI5NTA5OTg3NA==.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2457749367","pubTimestamp":1722848760,"sourceInfo":null,"weMediaInfo":{"media_name":"金吾财讯","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾财讯 | 上海医药(02607)公布，控股子公司上海新亚药业闵行有限公司，收到国家药品监督管理局颁发的关于甲钴胺片的《药品补充申请批准通知书》(通知书编号：2024B03245)，该药品通过仿制药一致性评价。据悉甲钴胺片主要用于周围神经病，由日本卫材研发，最早于1981年在日本上市。2022年11月，新亚闵行就该药品仿制药一致性评价向国家药监局提出申请并获受理。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"601607":"上海医药","BK1197":"保健护理产品经销商","BK0028":"国家队","BK0209":"零售","BK0187":"一线龙头","BK0020":"浦东新区","02607":"上海医药","HSTECH":"恒生科技指数","BK0183":"MSCI概念","BK0184":"上海国资改革","BK0012":"证金概念","BK0196":"行业龙头","YANG":"三倍做空富时中国ETF-Direxion","BK0097":"医药电商","BK0099":"上海本地重组","BK0175":"白马股","BK0188":"融资融券","HSCEI":"国企指数"},"translate_title":"[Hong Kong Stock Connect] The mecobalamin tablets developed by a subsidiary of Shanghai Pharmaceuticals (02607) passed the generic drug consistency evaluation of the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"YANG":1,"HSTECH":1,"HSCEI":1,"02607":1},"content_text":"金吾财讯 | 上海医药(02607)公布，控股子公司上海新亚药业闵行有限公司，收到国家药品监督管理局颁发的关于甲钴胺片的《药品补充申请批准通知书》(通知书编号：2024B03245)，该药品通过仿制药一致性评价。据悉甲钴胺片主要用于周围神经病，由日本卫材研发，最早于1981年在日本上市。2022年11月，新亚闵行就该药品仿制药一致性评价向国家药监局提出申请并获受理。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2457749367"}